Journal Article |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
360 |
Are novel drugs more risky for patients than less novel drugs? |
0 |
0 |
0 |
29 |
0 |
0 |
2 |
112 |
Eliminating the U.S. drug lag: Implications for drug safety |
0 |
0 |
0 |
13 |
0 |
0 |
2 |
108 |
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity |
0 |
0 |
1 |
7 |
0 |
0 |
3 |
56 |
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity |
0 |
0 |
0 |
2 |
1 |
2 |
4 |
19 |
Firm Characteristics and the Speed of FDA Approval |
0 |
0 |
0 |
41 |
0 |
1 |
2 |
142 |
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? |
0 |
0 |
2 |
3 |
0 |
0 |
6 |
29 |
Pharmaceutical Policy Change and the Safety of New Drugs |
0 |
0 |
1 |
7 |
0 |
1 |
4 |
66 |
Political Influence and Regulatory Policy: The 1984 Drug Legislation |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
176 |
Regulatory Agency Discretion among Competing Industries: Inside the FDA |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
187 |
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
120 |
Substitution in Regulatory Agencies: FDA Enforcement Alternatives |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
200 |
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D |
0 |
0 |
0 |
12 |
0 |
1 |
1 |
70 |
The risk we bear: The effects of review speed and industry user fees on new drug safety |
0 |
0 |
0 |
26 |
0 |
1 |
4 |
137 |
Total Journal Articles |
0 |
0 |
4 |
165 |
1 |
6 |
30 |
1,782 |